Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.32 |
| ▸ | CDK2 | P24941 | 8/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.30 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252624 | 0.86 | NR1H2 (0.46) | NR1H2CCNA2CDK2CCNA1PDK2 | |
| SCHEMBL30706326 | 0.71 | CYP1A2 (0.46) | — | |
| SCHEMBL30706322 | 0.71 | NR1H2 (0.35) | NR1H2CCNA2CDK2CCNA1 | |
| SCHEMBL30706325 | 0.71 | CYP1A2 (0.46) | — | |
| SCHEMBL30706332 | 0.70 | KDM4E (0.41) | CCNA2CDK2CCNA1 | |
| SCHEMBL30706324 | 0.70 | NR1H2 (0.34) | NR1H2CCNA2CDK2CCNA1 | |
| SCHEMBL30706328 | 0.70 | LCK (0.38) | PDK2 | |
| SCHEMBL30706327 | 0.70 | LCK (0.38) | PDK2 | |
| SCHEMBL30706321 | 0.69 | DGAT1 (0.38) | NR1H2CCNA2CDK2CCNA1 | |
| SCHEMBL29573372 | 0.64 | NAMPT (0.40) | NR1H2CCNA2CDK2CCNA1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | claimed |
| EP-3885347-B1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORP (JP) | 2023-11-22 | — | — | EP | claimed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| CN-114174281-B | Degradation agent for cyclin-dependent kinase 7 (CDK 7) and use thereof | 达纳-法伯癌症研究公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-3885347-B1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORP (JP) | 2023-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | NR1H2 2934/4885CCNA2 41/4885CDK2 7/4885 |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | NR1H2 1341/4885CCNA2 2036/4885CDK2 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.